Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults. Issue 4 (21st December 2018)

• Record Type: Journal Article
• Authors: Zullo, Andrew R.; Zhang, Tingting; Lee, Yoojin; McConeghy, Kevin W.; Daiello, Lori A.; Kiel, Douglas P.; Mor, Vincent; Berry, Sarah D.
• Is Part Of: Journal of the American Geriatrics Society. Volume 67:Issue 4(2019)
• Page Start: 768
• Page End: 776
• Publication Date: 2018-12-21
• Subjects: bisphosphonates -- hip fracture -- nonvertebral fracture -- nursing homes -- Medicare; Geriatrics -- Periodicals; 618.97
• DOI: 10.1111/jgs.15725
• Languages: English
• ISSNs: 0002-8614

Abstract

Abstract : BACKGROUND: Bisphosphonates are seldom used in frail, older adults, in part due to lack of direct evidence of efficacy in this population and increasing concerns about safety. OBJECTIVE: We estimated the effects of bisphosphonates on hip fractures, nonvertebral fractures, and severe esophagitis among frail, older adults. DESIGN: Population‐based retrospective cohort using 2008 to 2013 linked national Minimum Data Set assessments; Online Survey Certification and Reporting System records; and Medicare claims. SETTING: US nursing homes (NHs). PARTICIPANTS: Long‐stay NH residents 65 years and older without recent osteoporosis medication use (N = 24, 571). Bisphosphonate initiators were 1:1 propensity score matched to calcitonin initiators (active comparator). MEASUREMENTS: Hospitalized hip fracture, nonvertebral fracture, and esophagitis outcomes were measured using part A claims. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated, controlling for over 100 baseline characteristics. RESULTS: The matched cohort included 5209 new bisphosphonate users and an equal number of calcitonin users (mean age [SD] = 85 [8] years; 87% female; 52% moderate‐severe cognitive impairment). Over a mean follow‐up of 2.5 (SD = 1.7) years, 568 residents (5.5%) had a hip fracture, 874 (8.4%) had a nonvertebral fracture, and 199 (1.9%) had a hospitalized esophagitis event. Users of bisphosphonates were less likely than calcitonin users to experience hip fracture (HR = 0.83; 95% CI = 0.71‐0.98), with an average gain in time without fracture of 28.4 days (95% CI = 6.0‐50.8 days). Bisphosphonate and calcitonin users had similar rates of nonvertebral fracture (HR = 0.91; 95% CI = 0.80‐1.03) and esophagitis events (HR = 1.11; 95% CI = 0.84‐1.47). The effects of bisphosphonates on fractures and esophagitis were generally homogeneous across subgroups, including those defined by age, sex, history of prior fracture, and baseline fracture risk. CONCLUSIONS: Use of bisphosphonates is associated with a meaningful reduction in hip fracture among frail, older adults, but little difference in nonvertebral fracture or severe esophagitis. J Am Geriatr Soc 67:768–776, 2019.